Scholars Central

ArticlePublished 26 Dec 2016

Randomized observational study to assess the efficacy and safety of the association of fortigel (10 g) and fucoidan (100 mg) in patients with gonarthrosis

Authors: Martin-Martin LS, Pierluigi B, La Medica C, Melis G, Nuvoli G, Piccinni V, Pietrapertosa M, Vincenti B & Vinicola V

International Journal of Clinical Rheumatology

Volume 11 · Issue 6 · Pages 102

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: In order to further elucidate the efficacy and safety of some nutritional supplements on gonarthrosis, we have conducted a preliminary randomized multicenter (n=9) observational study comparing the effects of an association of Fortigel® (10 g) and Fucoidan (100 mg) (ACTEN®) versus another commonly therapeutically used formulation based on Glucosamine (500 mg), Chondroitin Sulfate (400 mg) hyaluronic Acid (50 mg) and Vitamin C (100 mg) (COMBIART™). Patients and Methods: The protocol was administered over a 12-weeks period in a population (n=126) aged 40-65 years, with diagnosed mild-to-moderate osteoarthritis (OA) of the knee (grade 2-3 of Kellgren Lawrence grading scale). Safety was measured by closely monitoring adverse events. Efficacy was measured by grading evaluations, at basal, 1 month and 3 months controls, of the Visual Analog Scale (VAS) and the Lequesne algofunctional index for severity of osteoarthritis (LAI) for articular functionality. Results: Both groups showed an important reduction (P<0.0001) in the mean visual analog scale values at T1 (28.5% ACTEN®, 21.3% COMBIART at 1 month) and T3 (49.4% ACTEN®, 40.1% COMBIART™ at 3 months), as well as a marked reduction in the Lequesne algofunctional index means (P<0.0001) (ACTEN® 28.9% T1 44.9% T3, COMBIART™ T1 21.3% T3 37%). The effect seems to be time dependent, as the mean values decrease further for both parameters from T1 to T2 (P<0.0001, for VAS for both groups; P 0.0011 for ACTEN® group, P 0.0064 Control group for LAI). No statistically significant difference was found between the ACTEN® group and the COMBIART™ group at time T1 or T3. These interesting preliminary data will be further investigated on a larger scale. Conclusions: Fortigel® (10 g) and Fucoidan (100 mg) (ACTEN®) taken as oral nutritional supplements have a significant impact as therapeutic intervention for knee osteoarthritis as indicated by the marked decrease in VAS and LAI values over the course of the treatment. A similar effect, as expected, has been confirmed in the COMBIART™ group, and no statistically significant difference has been detected between the two groups.

Subjects

Rheumatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Clinical Rheumatology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Clinical Rheumatology
  • SubjectRheumatology
  • BylineArticles whose byline prints “Martin-Martin LS”
  • BylineArticles whose byline prints “Pierluigi B”
  • BylineArticles whose byline prints “La Medica C”
  • BylineArticles whose byline prints “Melis G”
  • BylineArticles whose byline prints “Nuvoli G”
  • BylineArticles whose byline prints “Piccinni V”
  • BylineArticles whose byline prints “Pietrapertosa M”
  • BylineArticles whose byline prints “Vincenti B & Vinicola V”